Home › Trial NCT05880043
GIC-102, Intravenous Allogeneic NK Cells, in Subjects With Advanced Solid Cancers and R/R Hematologic Malignancies
- Trial IDNCT05880043
- StatusUnknown
- PhasePhase 1/2
- Study typeInterventional
- SponsorGI Cell, Inc.
- Enrollment50
- Start date2023-04-28
- ConditionsAdvanced Solid Tumors · Relapsed/Refractory Non-Hodgkin Lymphoma · Relapsed/Refractory Multiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.